PHI-501

CAT: 0804-HY-153858Size: 1 EachDry Ice: NoHazardous: No
CAT#:0804-HY-153858Size:1 Each
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
PHI-501 is a dual inhibitor targeting RAF/DDR. PHI-501 exhibits significant anti-proliferative effects in melanoma cell lines and significantly inhibits the colony formation of drug-resistant cells. PHI-501 strongly inhibits ERK and AKT phosphorylation. PHI-501 downregulates the gene sets in drug-resistant cells of TNFA-NFKB, IL6-JAK-STAT3, and KRAS signaling pathways as well as the epithelial-mesenchymal transition (EMT) signaling pathways. PHI-501 demonstrates significant anti-tumor effects in the SK-MEL3DR xenograft model. PHI-501 can be used for research on the problem of drug resistance in melanoma[1].
CAS Number
[2470433-36-2]
UNSPSC
12352005
Target
Discoidin Domain Receptor; Interleukin Related; JAK; MEK; Raf; Ras; STAT; TNF Receptor
Related Pathways
Apoptosis; Epigenetics; GPCR/G Protein; Immunology/Inflammation; JAK/STAT Signaling; MAPK/ERK Pathway; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt
Field of Research
Cancer
Smiles
O=C(C1=CC=CC(C(F)(F)F)=C1)NC2=CC=C(C)C(C3=CC4=C(C(N3C)=O)N=C(NC5=CN=C(C)C=C5)N=C4)=C2
Molecular Formula
C29H23F3N6O2
Molecular Weight
544.53
References & Citations
[1]Kim SM, et al. PHI-501 is a novel potent next-generation pan-RAF/DDRs inhibitor, and overcomes resistance to RAF or MEK inhibitor in melanoma via dual inhibition of RAF and DDR1/2 signaling. Cancer Research. 2024 Mar 22;84 (6_Supplement) :4657-.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
IL-6; K-Ras; Raf; STAT3

Popular Products